<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242983</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000450163</org_study_id>
    <secondary_id>NHOK-BRI-LC03-01</secondary_id>
    <nct_id>NCT00242983</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients Who Are Receiving Either Vinorelbine, Gemcitabine, and Docetaxel or Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>Assessment of Quality of Life (QOL) in Patients Registered With &quot;Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer (JMTO LC00-03)&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Hospital Organization Kinki-chuo Chest Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying quality-of-life in patients undergoing cancer treatment may help identify
      the intermediate and long-term effects of treatment on patients with cancer.

      PURPOSE: This clinical trial is studying quality of life in patients who are receiving either
      vinorelbine, gemcitabine, and docetaxel or paclitaxel and carboplatin for advanced non-small
      cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the quality of life of patients with advanced non-small cell lung cancer treated
           with vinorelbine, gemcitabine, and docetaxel vs paclitaxel and carboplatin on protocol
           JMTO-LC00-03.

      OUTLINE: This is a multicenter study. Patients receive treatment on protocol JMTO-LC00-03.

      Quality of life is assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L),
      FACT-Taxane, and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp)
      questionnaires at baseline, weeks 9 and 18, and at the completion of treatment.

      PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2004</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Change in the total score from baseline measured by the Functional Assessment of Cancer Therapy-Lung (FACT-L), FACT-Taxane, and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp) questionnaires at 9, 18, and 22 weeks or withdrawal</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the subscale from baseline of these questionnaires at 9, 18, and 22 weeks or withdrawal</measure>
  </secondary_outcome>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed primary non-small cell lung cancer,
             including any of the following:

               -  Newly diagnosed selected stage IIIB (T4 lesion due to malignant pleural effusion)
                  disease

               -  Newly diagnosed stage IV disease

               -  Recurrent disease after prior surgery and/or radiotherapy

          -  Any of the following cellular subtypes are allowed:

               -  Adenocarcinoma

               -  Large cell carcinoma

               -  Squamous cell carcinoma

               -  Unspecified carcinoma

          -  Enrolled on protocol JMTO-LC00-03

        PATIENT CHARACTERISTICS:

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        PRIOR CONCURRENT THERAPY:

        Radiotherapy

          -  See Disease Characteristics

        Surgery

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masaaki Kawahara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Hospital Organization - Osaka National Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toyohashi Municipal Hospital</name>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichinomiyanishi Hospital</name>
      <address>
        <city>Aichi</city>
        <zip>491-0201</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical College</name>
      <address>
        <city>Asahikawa</city>
        <zip>078 8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba-ken</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shikoku Cancer Center Hospital</name>
      <address>
        <city>Ehime</city>
        <zip>790-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Nishigunma National Hospital</name>
      <address>
        <city>Gumna</city>
        <zip>377-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Cancer Center</name>
      <address>
        <city>Gunma</city>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Dohoku National Hospital</name>
      <address>
        <city>Hokkaido</city>
        <zip>070-0901</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Junshinkai Tsuna Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takarazuka Municipal Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>665-0827</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujisawa City Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>251-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Minamikyoto Medical Center</name>
      <address>
        <city>Kyoto</city>
        <zip>610-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center</name>
      <address>
        <city>Miyagi</city>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Okayama Medical Center</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka-shi</city>
        <zip>558-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Kosei Nenkin Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cardiovascular and Respiratory Center</name>
      <address>
        <city>Saitama</city>
        <zip>360-0105</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>160</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koseiren Takaoka Hospital</name>
      <address>
        <city>Toyama</city>
        <zip>933-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

